Got $1,000? This Agentic AI Growth Stock Is Down 87% From Its Highs

Key metrics: ARR $1.85B (up 11% YoY), Q4 fiscal 2026 revenue $481M (up 14% YoY) and net income $104.5M vs $51.8M a year ago, with net income turning positive over the last 12 months. Management is pivoting UiPath’s RPA platform to manage agentic AI agents and projects FY2027 revenue of $1.75B vs $1.61B in FY2026. Despite operational recovery signs, the stock is down ~87% from its highs (down >35% in 2026) and the Yahoo! Finance consensus target of $13.81 implies only ~24% upside, leading the author to pass on buying.

Analysis

Agentic AI is re-pricing the execution layer: commoditization pressure will hit low-value, unobserved automation first, while a thin set of orchestration/control-plane features (auditability, transactionality, SSO/role mapping, SLA guarantees) will retain pricing power. That creates a bifurcation in TAM — high-volume, low-value automation becomes a cloud/compute play (wins for GPU/cloud providers), while regulated enterprise workflows remain a differentiated product that can command premium TCVs if the vendor proves reliability and governance.

Secondary supply-chain effects matter: sustained agent deployment materially raises cloud/GPU consumption, which should continue to skew enterprise spend toward hyperscalers and chip vendors, accelerating revenue for NVDA and increasing bargaining leverage for cloud providers. Conversely, broad embedding of agent primitives into SaaS suites (CRM/ERP/vertical apps) is the fastest path to RPA margin compression — an outcome that would force standalone orchestration vendors into partnership or M&A paths within 12–36 months.

Near-term catalysts to watch are not just bookings but dollar-based retention on agent-enabled workflows, proof points on cost-per-transaction versus scripted RPA, and strategic distribution deals with hyperscalers or ERP vendors; these are binary within the next 6–18 months and will create meaningful re-rating events. Tail risks include rapid maturation of open-source agent frameworks combined with cloud credits, which can compress license economics quickly, and regulatory scrutiny of autonomous decision traces that could either entrench incumbents or raise switching costs.

The market likely overshoots on both sides: downside narratives underrate enterprise switching costs and compliance-driven stickiness, while optimism around agent-native disruption understates the technical burden of safe, auditable execution at scale. That sets up asymmetric trades where controlled optionality (long-dated calls or call spreads) plus short exposure funded by long positions in infrastructure winners offers the cleanest risk/reward profile over 9–24 months.

Key Decisions for Investors

• Short PATH equity on any material rally into earnings or guidance (initiate on >10% intraday rally). Size as a tactical book (max 1–1.5% NAV). Target 6–12 month horizon; stop if news shows multi-year hyperscaler partnership or materially improved dollar-based retention. R/R: asymmetric — limited carrying cost vs high downside if licensing economics compress.
• Buy NVDA 9–12 month call spread to capture ongoing GPU/cloud tailwinds from agent deployments. Allocate 1–2% NAV, aim for ~2–3x payoff vs premium paid; hedge portion of short PATH exposure. Catalyst: continued beat-and-raise on data-center revenues; risk = event-driven GPU demand miss.
• Initiate a modest long in IBM (12–24 month) as a hedge to capture hybrid-cloud orchestration upside and potential ISV partnerships. Size small (0.5–1% NAV). Rationale: platform buyers benefit if enterprises prefer integrated compliance/orchestration in hybrid environments; payoff if IBM wins strategic deals.
• Buy PATH 18–24 month OTM call spread (financed with small short-term premium sales if comfortable) as low-cost asymmetric exposure to a recovery/acquisition scenario. Limit premium outlay to <0.5% NAV. This preserves downside while offering multi-bagger upside if enterprise lock-in or strategic M&A materializes within two years.